Abstract
As some drugs have narrow therapeutic windows and high inter-patient exposure variability, they require concentration measurements to ensure their safe and effective dosing. To improve on the current practice of sparse blood sampling, we are developing wearable ‘patches’ bearing electrochemical aptamer-based sensors on small, solid needles. Here we describe a pilot phase trial testing their safety and performance in six healthy human participants. The patches were found to be safe and nearly pain free, and they captured concentrations of vancomycin in the dermal interstitial fluid with 5-minute resolution over 24 hours, although, due to sensor degradation, we primarily describe data from the first 12 hours after insertion. Fitting interstitial fluid and plasma concentrations to compartmental pharmacokinetic models revealed distribution and clearance dynamics that are not detected with current sparse sampling approaches. Patches placed at different bodily sites exhibited consistent trends both within and across participants. With further testing and optimization, including real-time wireless data transmission, such patches could aid precision dosing of vancomycin and other drugs with narrow therapeutic windows. Australian New Zealand Clinical Trials Registry registration: ACTRN12622000280707.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout





Data availability
The data supporting the findings of the study are included in the article and its Supplementary Information. The clinical study protocol is also included as supplementary information, as is a repository link to the custom code employed in this study76. The clinical study (ACTRN12622000280707) can be publicly searched on the Australian New Zealand Clinical Trials Registry. The deidentified individual participant concentration versus time data that underlie the results reported in this article are available in the supplementary information files. Limited further details are available upon request by researchers who provide a methodologically sound proposal. The data will be available beginning 3 months after publication with no end date. Proposals should be directed to info@nutromics.com. To gain access, data requestors will need to sign a data access agreement. Source data are provided with this paper.
Code availability
The custom analytical code used for pharmacokinetic modeling is available via Zenodo at https://doi.org/10.5281/zenodo.17931398 (ref. 76).
References
Abdel Jalil, M. H. et al. Vancomycin prescribing and therapeutic drug monitoring: challenges of real clinical practice. PLoS ONE 18, e0285717 (2023).
Chan, J. O. S. et al. Barriers and facilitators of appropriate vancomycin use: prescribing context is key. Eur. J. Clin. Pharmacol. 74, 1523–1529 (2018).
Reuter, S. E. et al. Optimal practice for vancomycin therapeutic drug monitoring: position statement from the anti-infectives committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther. Drug Monit. 44, 121–132 (2022).
Yi, Z.-M. et al. Status and quality of guidelines for therapeutic drug monitoring based on AGREE II instrument. Clin. Pharmacokinet. 62, 1201–1217 (2023).
Pai Mangalore, R. et al. Beta-lactam antibiotic therapeutic drug monitoring in critically ill patients: a systematic review and meta-analysis. Clin. Infect. Dis. 75, 1848–1860 (2022).
Sanz-Codina, M., Bozkir, H. Ö, Jorda, A. & Zeitlinger, M. Individualized antimicrobial dose optimization: a systematic review and meta-analysis of randomized controlled trials. Clin. Microbiol. Infect. 29, 845–857 (2023).
Takahashi, N. et al. Efficacy of therapeutic drug monitoring-based antibiotic regimen in critically ill patients: a systematic review and meta-analysis of randomized controlled trials. J. Intensive Care 11, 48 (2023).
Begg, E. J., Barclay, M. L. & Kirkpatrick, C. M. J. The therapeutic monitoring of antimicrobial agents. Br. J. Clin. Pharmacol. 52, 35–43 (2001).
Xiao, Y., Lubin, A. A., Heeger, A. J. & Plaxco, K. W. Label-free electronic detection of thrombin in blood serum by using an aptamer-based sensor. Angew. Chem. Int. Ed. 44, 5456–5459 (2005).
Alkhamis, O. et al. High-affinity aptamers for in vitro and in vivo cocaine sensing. J. Am. Chem. Soc. 146, 3230–3240 (2024).
Arroyo-Currás, N. et al. Real-time measurement of small molecules directly in awake, ambulatory animals. Proc. Natl Acad. Sci. USA 114, 645–650 (2017).
Arroyo-Currás, N. et al. Subsecond-resolved molecular measurements in the living body using chronoamperometrically interrogated aptamer-based sensors. ACS Sens. 3, 360–366 (2018).
Arroyo-Currás, N. et al. High-precision control of plasma drug levels using feedback-controlled dosing. ACS Pharmacol. Transl. Sci. 1, 110–118 (2018).
Chamorro-Garcia, A. et al. Real-time, seconds-resolved measurements of plasma methotrexate in situ in the living body. ACS Sens. 8, 150–157 (2023).
Dauphin-Ducharme, P. et al. Electrochemical aptamer-based sensors for improved therapeutic drug monitoring and high-precision, feedback-controlled drug delivery. ACS Sens. 4, 2832–2837 (2019).
Gerson, J. et al. High-precision monitoring of and feedback control over drug concentrations in the brains of freely moving rats. Sci. Adv. 9, eadg3254 (2023).
Gerson, J. et al. A high-precision view of intercompartmental drug transport via simultaneous, seconds-resolved, in situ measurements in the vein and brain. Br. J. Pharmacol. 181, 3869–3885 (2024).
Idili, A. et al. Seconds-resolved pharmacokinetic measurements of the chemotherapeutic irinotecan in situ in the living body. Chem. Sci. 10, 8164–8170 (2019).
Idili, A., Gerson, J., Kippin, T. & Plaxco, K. W. Seconds-resolved, in situ measurements of plasma phenylalanine disposition kinetics in living rats. Anal. Chem. 93, 4023–4032 (2021).
Li, S. et al. Implantable hydrogel-protective DNA aptamer-based sensor supports accurate, continuous electrochemical analysis of drugs at multiple sites in living rats. ACS Nano 17, 18525–18538 (2023).
Li, H. et al. High frequency, calibration-free molecular measurements in situ in the living body. Chem. Sci. 10, 10843–10848 (2019).
Lin, S. et al. Wearable microneedle-based electrochemical aptamer biosensing for precision dosing of drugs with narrow therapeutic windows. Sci. Adv. 8, eabq4539 (2022).
Qin, S.-N. et al. Real-time monitoring of daunorubicin pharmacokinetics with nanoporous electrochemical aptamer-based sensors in vivo. Sens. Actuators B Chem. 411, 135710 (2024).
Roehrich, B. et al. Calibration-free, seconds-resolved in vivo molecular measurements using Fourier-transform impedance spectroscopy interrogation of electrochemical aptamer sensors. ACS Sens. 8, 3051–3059 (2023).
Seo, J.-W. et al. Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals. Sci. Adv. 8, eabk2901 (2022).
Shaver, A. et al. Optimization of vancomycin aptamer sequence length increases the sensitivity of electrochemical, aptamer-based sensors in vivo. ACS Sens. 7, 3895–3905 (2022).
Vieira, P. A. et al. Ultra-high-precision, in-vivo pharmacokinetic measurements highlight the need for and a route toward more highly personalized medicine. Front. Mol. Biosci. 16, 6 (2019).
Bakhshandeh, F. et al. Wearable Aptalyzer integrates microneedle and electrochemical sensing for in vivo monitoring of glucose and lactate in live animals. Adv. Mater. 36, 2313743 (2024).
Emmons, N. A. et al. Feedback control over plasma drug concentrations achieves rapid and accurate control over solid-tissue drug concentrations. ACS Pharmacol. Transl. Sci. 8, 1416−1423 (2025).
Kiang, T. K. L., Schmitt, V., Ensom, M. H. H., Chua, B. & Häfeli, U. O. Therapeutic drug monitoring in interstitial fluid: a feasibility study using a comprehensive panel of drugs. J. Pharm. Sci. 101, 4642–4652 (2012).
Tran, B. Q. et al. Proteomic characterization of dermal interstitial fluid extracted using a novel microneedle-assisted technique. J. Proteome Res. 17, 479–485 (2018).
Sprunger, Y., Longo, J., Saeidi, A. & Ionescu, A. M. Bridging blood and skin: biomarker profiling in dermal interstitial fluid (dISF) for minimally invasive diagnostics. Biosensors 15, 301 (2025).
Samant, P. P. et al. Sampling interstitial fluid from human skin using a microneedle patch. Sci. Transl. Med. 12, eaaw0285 (2020).
Wu, Z. et al. Interstitial fluid-based wearable biosensors for minimally invasive healthcare and biomedical applications. Commun. Mater. 5, 33 (2024).
U.S. Food and Drug Administration. Device Classification Under Section 513(f)(2) (De Novo): Biolinq Shine Autonomous Time-in-Range Microsensor. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN240080 (2025).
Zhu, J. et al. Gelatin methacryloyl microneedle patches for minimally invasive extraction of skin interstitial fluid. Small 16, 1905910 (2020).
Friedel, M. et al. Continuous molecular monitoring of human dermal interstitial fluid with microneedle-enabled electrochemical aptamer sensors. Lab. Chip 23, 3289–3299 (2023).
Keyvani, F. et al. Integrated electrochemical aptamer biosensing and colorimetric pH monitoring via hydrogel microneedle assays for assessing antibiotic treatment. Adv. Sci. 11, 2309027 (2024).
Ranamukhaarachchi, S. A. et al. Integrated hollow microneedle-optofluidic biosensor for therapeutic drug monitoring in sub-nanoliter volumes. Sci. Rep. 6, 29075 (2016).
Yuan, R. et al. Integrated microneedle aptasensing platform toward point-of-care monitoring of bacterial infections and treatment. ACS Sens. 10, 5684–5693 (2025).
Reynoso, M. et al. 3D-printed, aptamer-based microneedle sensor arrays using magnetic placement on live rats for pharmacokinetic measurements in interstitial fluid. Biosens. Bioelectron. 244, 115802 (2024).
Rybak, M. J. et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 77, 835–864 (2020).
D’Amico, H. et al. Acute kidney injury associated with area under the curve versus trough monitoring of vancomycin in obese patients. Antimicrob. Agents Chemother. 66, e00886–21 (2022).
Neely, M. N. et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob. Agents Chemother. 62, e02042-17 (2018).
Pai, M. P., Neely, M., Rodvold, K. A. & Lodise, T. P. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv. Drug Deliv. Rev. 77, 50–57 (2014).
Stewart, J. J. et al. A Canadian perspective on the revised 2020 ASHP–IDSA–PIDS–SIDP guidelines for vancomycin AUC-based therapeutic drug monitoring for serious MRSA infections. J. Assoc. Med. Microbiol. Infect. Dis. Can. 6, 3–9 (2021).
Stocker, S. L. et al. Evaluation of a pilot vancomycin precision dosing advisory service on target exposure attainment using an interrupted time series analysis. Clin. Pharmacol. Ther. 109, 212–221 (2021).
Aljefri, D. M. et al. Vancomycin area under the curve and acute kidney injury: a meta-analysis. Clin. Infect. Dis. 69, 1881–1887 (2019).
Drennan, P. G., Begg, E. J., Gardiner, S. J., Kirkpatrick, C. M. J. & Chambers, S. T. The dosing and monitoring of vancomycin: what is the best way forward? Int. J. Antimicrob. Agents 53, 401–407 (2019).
Bradley, N., Lee, Y. & Sadeia, M. Assessment of the implementation of AUC dosing and monitoring practices with vancomycin at hospitals across the United States. J. Pharm. Pract. 35, 864–869 (2022).
Dauphin-Ducharme, P., Ploense, K. L., Arroyo-Currás, N., Kippin, T. E. & Plaxco, K. W. Electrochemical aptamer-based sensors: a platform approach to high-frequency molecular monitoring in situ in the living body. in Biomedical Engineering Technologies: Volume 1 (eds Ossandon, M. R., Baker, H. & Rasooly, A.) 479–492 (Springer, 2022).
U.S. Food and Drug Administration. Bioanalytical method validation: guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry (2018).
Rüsch, D., Koch, T., Spies, M. & Eberhart, L. H. J. Pain during venous cannulation. Dtsch. Arztebl. Int. 114, 605–611 (2017).
Leung, K. K., Downs, A. M., Ortega, G., Kurnik, M. & Plaxco, K. W. Elucidating the mechanisms underlying the signal drift of electrochemical aptamer-based sensors in whole blood. ACS Sens. 6, 3340–3347 (2021).
Leung, K. K. et al. The use of xenonucleic acids significantly reduces the in vivo drift of electrochemical aptamer-based sensors. Angew. Chem. Int. Ed. 63, e202316678 (2024).
Pham, J. D. et al. On the blood components contributing to the drift of electrochemical aptamer-based biosensors. ACS Sens. 10, 5160–5165 (2025).
Ningrum, V. D. A., Amalia, S. P. & Wibowo, A. Vancomycin bioanalysis for TDM services by using immunoassay and HPLC: a scoping review. Pharm. Educ. 24, 197–203 (2024).
Abraham, J. et al. Plasma and interstitial fluid population pharmacokinetics of vancomycin in critically ill patients with sepsis. Int. J. Antimicrob. Agents 53, 137–142 (2019).
Kolluru, C. et al. Monitoring drug pharmacokinetics and immunologic biomarkers in dermal interstitial fluid using a microneedle patch. Biomed. Microdevices 21, 14 (2019).
Ito, Y., Inagaki, Y., Kobuchi, S., Takada, K. & Sakaeda, T. Therapeutic drug monitoring of vancomycin in dermal interstitial fluid using dissolving microneedles. Int. J. Med. Sci. 13, 271–276 (2016).
Hariri, G. et al. Narrative review: clinical assessment of peripheral tissue perfusion in septic shock. Ann. Intensive Care 9, 37 (2019).
Heller, A. Integrated medical feedback systems for drug delivery. AIChE J. 51, 1054–1066 (2005).
D’Souza, D., Thaivalappil Padmanabhan, P., Batchelor, R. & Yin, W. Aptamer sequences and uses thereof. International patent, WO2025123084 (2025).
Bakestani, R. M. et al. Carboxylate-terminated electrode surfaces improve the performance of electrochemical aptamer-based sensors. ACS Appl. Mater. Interfaces 17, 8706–8714 (2025).
Groenendaal, W., von Basum, G., Schmidt, K. A., Hilbers, P. A. J. & van Riel, N. A. W. Quantifying the composition of human skin for glucose sensor development. J. Diabetes Sci. Technol 4, 1032–1040 (2010).
Friedel, M. et al. Opportunities and challenges in the diagnostic utility of dermal interstitial fluid. Nat. Biomed. Eng. 7, 1541–1555 (2023).
Oyaert, M. et al. Factors impacting unbound vancomycin concentrations in different patient populations. Antimicrob. Agents Chemother. 59, 7073–7079 (2015).
Butterfield, J. M. et al. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob. Agents Chemother. 55, 4277–4282 (2011).
Urakami, T., Oka, Y., Matono, T. & Aoki, Y. Factors affecting free vancomycin concentration and target attainment of free area under the concentration-time curve. J. Pharm. Health Care Sci. 11, 13 (2025).
Fetter, L. C., McDonough, M. H., Kippin, T. E. & Plaxco, K. W. Effects of physiological-scale variation in cations, pH, and temperature on the calibration of electrochemical aptamer-based sensors. ACS Sens. 9, 6675–6684 (2024).
Virtanen, P. et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat. Methods 17, 261–272 (2020).
Ljung, L. System Identification: Theory for the User 2nd edn (Prentice Hall, 1999).
Ogata, K. Modern Control Engineering 5th edn (Prentice Hall, 2010).
Wächter, A. & Biegler, L. T. On the implementation of an interior-point filter line-search algorithm for large-scale nonlinear programming. Math. Program. 106, 25–57 (2006).
Andersson, J. A. E., Gillis, J., Horn, G., Rawlings, J. B. &Diehl, M. CasADi: a software framework for nonlinear optimization and optimal control. Math. Program. Comput. https://doi.org/10.1007/s12532-018-0139-4 (2018).
Erdal, M. K. Custom code for "Pilot-phase clinical trial of wearable electrochemical-aptamer-based patches for continuous drug concentration measurement" by MA Booth, MK Erdal, SL Stocker, KW Plaxco et. al. Zenodo https://doi.org/10.5281/zenodo.17931397 (2025).
Acknowledgements
The authors acknowledge both our volunteer participants and the many other colleagues, consultants and collaborators who contributed to this effort. This includes the clinical study team at Monash Health (S. Warner, I. De Jong, K. Cabral, D. Suarez-Borinaga and V. Vasquez-Ferriggi), A. Beshiri, Cardinal Bioresearch, G. Chiampas, L. Chiampas, C. Conway, R. Crowder, C. Dejrangsi, R. Day, R. Kirubakaran, H. Mehta, V. Seah, A. Schafer, M. Stojanovic, R. Wilkie, P. Vranes and T. Yahya. Nutromics was awarded a CRC-P grant (Round 6) by the Australian Federal Government, which helped support the studies presented here. J.J.G. also acknowledges the Australian Research Council for an Industry Laureate Fellowship (IL240100091). R.H.B. is an Australian National Industry PhD candidate (award no. 35006).
Author information
Authors and Affiliations
Contributions
M.A.B., M.K.E., S.L.S. and K.W.P. were the primary authors of the manuscript. M.A.B. contributed to the sensor development and calibration. M.K.E. performed the pharmacokinetic modeling, with guidance from S.L.S., C.M.J.K. and K.W.P. G.C. led the engineering and sensor teams, which consisted of M.L., M.A.B., M.F., V.R.G., A.A., F.M., J.L., N.H., S.T., J.W., S.K., J.V.E., S.B., L.D., D.D., W.Y., P.T.P., R.H.B. and A.F. A.H., J.J.G., S.L.S. and K.W.P. contributed supervision and strategic scientific input. E.B., S.P., M.B., C.M.J.K. and S.L.S. performed or guided the design and conduct of the clinical trial. J.G. and T.E.K. performed the animal histology studies.
Corresponding authors
Ethics declarations
Competing interests
M.A.B., M.K.E., M.L., M.F., V.R.G., A.A., F.M., J.L., N.H., S.T., J.W., S.K., J.V.E., S.B., L.D., J.G., D.D., W.Y., P.T.P., R.H.B., A.F. and G.C. are employees of and own equity in Nutromics Pty Ltd., which is focused on the commercialization of EAB sensors for applications in biomedical research and clinical practice. E.B. was formerly an employee of Nutromics. A.H., V.R.G., C.M.J.K., J.J.G., S.L.S. and K.W.P. are paid consultants for and/or own equity in Nutromics Pty Ltd. The other authors declare no competing interests.
Peer review
Peer review information
Nature Biotechnology thanks the anonymous reviewers for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Information
Supplementary Figs. 1−12 and Supplementary Tables 1−8.
Supplementary Data
Clinical study protocol.
Source data
Source Data Fig. 1
Applied and estimated concentration values in µg ml−1.
Source Data Fig. 2
Concentration timecourses in plasma and ISF in µg ml−1.
Source Data Fig. 3
Various representative concentration timecourses in plasma and ISF in µg ml−1.
Source Data Fig. 4
Mean concentration timecourses in ISF for various patch positions in µg ml−1.
Source Data Fig. 5
Plasma and mean ISF concentration timecourse for each patch position on each volunteer.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Booth, M.A., Erdal, M.K., Larson, M. et al. Pilot phase clinical trial of a wearable, electrochemical aptamer-based patch for continuous drug concentration measurement. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03010-w
Received:
Accepted:
Published:
Version of record:
DOI: https://doi.org/10.1038/s41587-026-03010-w